Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C2B | O00750 | 17/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 16/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 14/20 | 1.00 |
| ▸ | MTOR | P42345 | 13/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.77 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17857347 | 0.92 | PIK3CD (1.00) | PIK3C2BPIK3CDPIK3CGMTORPIK3CB | |
| SCHEMBL17857391 | 0.91 | PIK3CD (1.00) | PIK3C2BPIK3CDPIK3CGMTORPIK3CB | |
| SCHEMBL17857093 | 0.91 | PIK3CD (0.82) | PIK3C2BPIK3CDPIK3CGMTORPIK3CB | |
| SCHEMBL17857346 | 0.89 | PIK3CD (0.83) | PIK3C2BPIK3CDPIK3CGMTORPIK3CB | |
| SCHEMBL17857384 | 0.87 | PIK3CD (1.00) | PIK3C2BPIK3CDPIK3CGMTORPIK3CB | |
| SCHEMBL21120043 | 0.85 | PIK3CD (0.73) | PIK3C2BPIK3CDPIK3CGMTORPIK3CB | |
| SCHEMBL17857089 | 0.84 | PIK3CD (0.72) | PIK3C2BPIK3CDPIK3CGMTORPIK3CB | |
| SCHEMBL21120274 | 0.83 | PIK3CD (0.73) | PIK3C2BPIK3CDPIK3CGMTORPIK3CB | |
| SCHEMBL17857023 | 0.81 | PIK3CD (0.82) | PIK3C2BPIK3CDPIK3CGMTORPIK3CB | |
| SCHEMBL17857635 | 0.81 | PIK3CD (0.81) | PIK3C2BPIK3CDPIK3CGMTORPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233862-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-03 | — | — | EP | disclosed |
| US-20180002336-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-04 | — | — | US | disclosed |
| WO-2016097347-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002336-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | PIK3CB, PIK3CD, PIK3CA | PIK3C2B 6/4885PIK3CD 2/4885PIK3CG 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.